The multicentre, randomised trial was conducted in China, but Sichuan-Kelun and Merck & Co will commercialise sac-TMT in other markets.
Pfizer is suing Novo Nordisk following the Danish pharma's last-minute bid to acquire Metsera, which Pfizer called “reckless” ...
D Molecular Therapeutics (4DMT) has announced an exclusive licence agreement with Otsuka Pharmaceutical to develop and market 4D-150.
IntoCell has announced a MoU with US-based contract development and manufacturing organisatioXcellon Biologics.
Bayer and BI have reported broadly similar efficacy outcomes for sevabertinib and Hernexeos in HER2-mutant NSCLC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback